(2024)
A systematic analysis of the landscape of synthetic lethality-driven precision oncology.
Med.
5,
1
(2023)
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER.
11,
10
(2023)
Prognostic implication of downregulated exosomal miRNAs in patients with sepsis: a cross-sectional study with bioinformatics analysis.
JOURNAL OF INTENSIVE CARE.
11,
1
(2023)
A landscape of response to drug combinations in non-small cell lung cancer.
NATURE COMMUNICATIONS.
14,
1
(2023)
Early infiltration of innate immune cells to the liver depletes HNF4a and promotes extra-hepatic carcinogenesis.
CANCER DISCOVERY.
22,
1
(2023)
Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma.
CELL REPORTS MEDICINE.
4,
2
(2022)
Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome.
MED.
4,
1
(2022)
CRBN is downregulated in lung cancer and negatively regulates TLR2, 4 and 7 stimulation in lung cancer cells.
CLINICAL AND TRANSLATIONAL MEDICINE.
12,
9
(2022)
USP15 negatively regulates lung cancer progression through the TRAF6-BECN1 signaling axis for autophagy induction.
CELL DEATH & DISEASE.
13,
4
(2022)
Deconvolving Clinically Relevant Cellular Immune Cross-talk from Bulk Gene Expression Using CODEFACS and LIRICS Stratifies Patients with Melanoma to Anti-PD-1 Therapy.
CANCER DISCOVERY.
12,
4
(2022)
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.
CANCER DISCOVERY.
12,
11
(2022)
USP8 regulates liver cancer progression via the inhibition of TRAF6-mediated signal for NF-κB activation and autophagy induction by TLR4.
Translational Oncology.
15,
1
(2021)
A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing.
NATURE COMMUNICATIONS.
12,
1
(2021)
Synthetic lethality-mediated precision oncology via the tumor transcriptome.
CELL.
184,
9
(2020)
Regulation of eIF2 alpha by RNF4 Promotes Melanoma Tumorigenesis and Therapy Resistance.
JOURNAL OF INVESTIGATIVE DERMATOLOGY.
140,
12
(2020)
Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors.
Nature Cancer.
1,
1
(2020)
p62 is Negatively Implicated in the TRAF6-BECN1 Signaling Axis for Autophagy Activation and Cancer Progression by Toll-Like Receptor 4 (TLR4).
CELLS.
9,
5
(2020)
Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma.
CANCER LETTERS.
478,
1
(2020)
Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma.
NATURE COMMUNICATIONS.
11,
1
(2019)
Translational reprogramming marks adaptation to asparagine restriction in cancer.
NATURE CELL BIOLOGY.
15,
1
